WO

Will Olsen

Founder of Engage Bio (Non-Viral DNA Therapies)

Menlo Park, California

Investor
VC
Founder

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $200,000.00

  • Max Investment:

    $300,000.00

  • Target Investment:

    $250,000.00

Skills

Clinical Trials
Clinical Development
Pharmaceutical Industry
CRO
Biotechnology
Oncology
Clinical Research
GCP
Life Sciences
FDA
SOP
Clinical Data Management
CTMS
ICH-GCP
Regulatory Affairs
Drug Development
Protocol
CRO Management
U.S. Food and Drug Administration (FDA)

Education

Investments

Granza Bio

Seed

Total Funding: $7.5M

Work Experience

Engage Bio

2021

  • Co-Founder & CEO

    2021

    Engage Bio is developing Tethosomes, the next generation of non-viral DNA medicines. Tethosomes are highly potent, non-immunogenic, redosable, and titratable. At Engage, we're focused on building genetic medicines that scale. www.engagebio.com

Pioneer Fund

2019

  • Venture Partner

    2019

Rejuvenation Technologies Inc.

2019 - 2021

  • Vice President of Development Operations

    2019 - 2021

    Developing TERT mRNA therapy to extend telomeres and increase the human healthspan.

Luminist (Acquired by DiscernDx)

2015 - 2020

  • Co-founder and Chief Operating Officer

    2015 - 2020

    Diagnostic platform for early detection of liver disease. Acquired by diagnostic developer DiscernDx.

Biorasi

2013 - 2015

  • Senior Program Manager

    2015 - 2015

    Designed and managed early-phase clinical programs. Participated in business development, including bid defenses and acting as technical sales lead.

  • Program Manager

    2013 - 2015

Mount Sinai Health System

2012 - 2013

  • Research Associate

    2012 - 2013

SpaceWorks Enterprises, Inc. (SEI)

2010 - 2010

  • Economic Analyst Intern

    2010 - 2010